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Background: A high-fat diet promotes postprandial systemic inflammation and metabolic endotoxemia. We investigated
the effects of three consecutive high-fat meals on endotoxemia, inflammation, vascular function, and postprandial lipid
metabolism in patients with type 1 diabetes.
Methods: Non-diabetic controls (n = 34) and patients with type 1 diabetes (n = 37) were given three high-caloric,
fat-containing meals during one day. Blood samples were drawn at fasting (8:00) and every two hours thereafter until
18:00. Applanation tonometry was used to assess changes in the augmentation index during the investigation day.
Results: Three consecutive high-fat meals had only a modest effect on serum LPS-activity levels and inflammatory
markers throughout the day in both groups. Of note, patients with type 1 diabetes were unable to decrease the
augmentation index in response to the high-fat meals. The most profound effects of the consecutive fat loads were
seen in chylomicron and HDL-metabolism. The triglyceride-rich lipoprotein remnant marker, apoB-48, was elevated
in patients compared to controls both at fasting (p = 0.014) and postprandially (p = 0.035). The activities of the
HDL-associated enzymes PLTP (p < 0.001), and CETP (p = 0.007) were higher and paraoxonase (PON-1) activity, an
anti-oxidative enzyme bound to HDL, decreased in patients with type 1 diabetes (p = 0.027).
Conclusions: In response to high-fat meals, early signs of vascular dysfunction alongside accumulation of chylomicron
remnants, higher augmentation index, and decreased PON-1 activity were observed in patients with type 1 diabetes.
The high-fat meals had no significant impact on postprandial LPS-activity in non-diabetic subjects or patients with
type 1 diabetes suggesting that metabolic endotoxemia may be more central in patients with chronic metabolic
disturbances such as obesity, type 2 diabetes, or diabetic kidney disease.
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Postprandial lipid accumulation, in the form of triglycer-
ide-rich lipoprotein (TRL) particles, is linked to high-fat
meal induced inflammation [1]. Absorption of bacterial
endotoxin/lipopolysaccharide (LPS) from the gut is postu-
lated to contribute to the development of chronic inflam-
mation in mammals after a high-fat diet [2,3].
Endotoxins are unique, fat-soluble glycolipids found in
the outer membrane of gram-negative bacteria. Systemi-
cally, endotoxins are primarily associated with circulating
LPS-binding proteins (LBP), the endothelium of blood
vessels, and lipoprotein particles. Binding of the LBP/LPS-
complex to Toll-like receptor 4 (TLR4) triggers an innate
immune response, characterized by cytokine release and
immune system activation [4]. Circulating HDL is likely
the most important factor involved in systemic endotoxin
neutralization [5], with both its quality and quantity influ-
encing clearance. High LPS-activity is further a risk factor
for incident type 2 diabetes and associated with obesity,
features of the metabolic syndrome, and the development
of kidney disease in patients with type 1 diabetes [6-8].
Patients with type 1 diabetes display an increased gut
permeability and decreased gastro-intestinal motility [9,10],
and children who develop type 1 diabetes have an altered
gut microbiota [11]. Importantly, these factors can directly
affect the translocation of LPS through the intestinal
epithelium. Furthermore elevated circulating inflammatory
cytokines and an increased arterial stiffness is evident in
patients with type 1 diabetes in response to acute hypergly-
caemia [12]. In addition lipoproteins in the postprandial
phase can directly influence the vascular endothelial cells
and interfere with their function [13,14]. It should also be
noted that most of the previous oral fat-load studies have
mainly focused on short term effects of a single fat load
[15]. Given this background, we wanted to investigate
whether the consumption of three consecutive high-fat
meals during one day would affect postprandial endotoxe-
mia, systemic inflammation, the augmentation index, and
lipid metabolism in patients with type 1 diabetes and non-
diabetic controls. We hypothesized that the three consecu-
tive high-fat meals would lead to an increase in systemic
endotoxin levels that would in turn be associated with
dyslipidemia, inflammation and vascular dysfunction. Here
we report that patients with type 1 diabetes display adverse
changes in HDL/chylomicron metabolism and impaired
vasodilation in response to three consecutive high-fat meals,
which may be early signs of cardiovascular disease. These
changes were independent of postprandial endotoxemia.
Material and methods
The study subjects were recruited by the Finnish Diabetic
Nephropathy Study (FinnDiane; www.finndiane.fi) and
involved 37 patients with type 1 diabetes and 34 non-
diabetic controls. All participants were Finnish citizens ofCaucasian background. Inclusion criteria for the study
were 1) age <65 years; 2) non-smoker; 3) no use of antibi-
otics during the past month; 4) no trips outside the
Nordic countries during the past month. Voluntary con-
trols were recruited from the laboratory personnel. Type 1
diabetes was defined as age at onset below 40 years and
permanent insulin treatment initiated within one year of
diagnosis. Participants completed a three-day food-record
prior to the day of investigation. Dietary intake was ana-
lysed as previously described [16]. Information on the use of
medication was recorded with a standardized questionnaire.
The study protocol was approved by the local ethical
committee (Ethics Committee, Department of Medicine,
Helsinki University Central Hospital), and all participants
gave an informed consent to participate in the study.
Participants were given three energy-rich meals
(2600 kcal) during one day: breakfast (at 8:00–965 kcal,
58% of total energy (E%) from fats), lunch (12:00–
870 kcal, 44 E% fats), and dinner (16:00–779 kcal, 46 E%
fats). Blood samples were drawn after overnight fasting
and every two hours until 18:00 hrs. Urine was collected
for 24-hours during the research day. Concentrations
of blood glucose, urinary albumin, and serum creatinine
as well as white blood cell counts (at 8:00 and 18:00)
were determined by routine methods at the labora-
tory of Helsinki University Central Hospital (HUSLAB,
Helsinki, Finland). Kidney status and function were
assessed by calculating the urinary albumin excretion
rate (AER) and the estimated glomerular filtration rate
(eGFR). Patients with an AER < 300 mg/24 h were
included in the analysis. Serum insulin concentrations
were determined with Wallac AutoDELFIA Insulin kit
(PerkinElmer, Turku, Finland) using an automatic ana-
lyser (Wallac 1235 Automatic Immunoassay System,
Wallac, Turku, Finland).
Serum triglycerides, total cholesterol, HDL-choles-
terol, apolipoprotein (apo) A-I (kit 981702; Konelab
Thermo Fischer, Vantaa, Finland), and apoB-100 (kit
981703; Konelab) concentrations were determined with
a Konelab analyser using automated enzymatic methods
(Thermo Scientific, Vantaa, Finland). Plasma apoB-48
concentrations were measured using an ELISA kit
(AKHB48, Shibayagi Co LtD, Shibukawa, Japan). ApoE
concentrations [17], as well as phospholipid transfer
protein (PLTP) [18], cholesteryl ester transfer protein
(CETP) [19,20], and paraoxonase (PON-1) [21] activities
were measured as previously reported. Fasting serum
lipid metabolites were analysed by nuclear magnetic
resonance (NMR) spectroscopy (NMR Metabolomics
Laboratory, Kuopio, Finland) as previously described
[22]. The size distribution of the HDL-subclasses was
very large HDL (average diameter of 14.3 nm), large
HDL (12.1 nm), medium HDL (10.9 nm), and small
HDL (8.7 nm).
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Serum LPS-activity was measured kinetically from 1:5
diluted serum samples with the Limulus amoebocyte lys-
ate assay (LAL, Hycult, Uden, the Netherlands). Briefly,
the colour formation at 405 nm was recorded every
2 min, for a total of 40 min. Since a postprandial rise in
triglyceride concentrations as well as hemolysis may lead
to arbitrarily high endotoxin levels in the LAL assay
[23], we subtracted the minimum absorbance value from
the maximum value, measuring the relative change of
absorbance in each sample.
Inflammatory factors
High sensitivity CRP (hsCRP kit 981798; Konelab)
concentrations were measured from serum samples with
a Konelab analyzer using automated enzymatic methods
(Thermo Scientific, Vantaa, Finland). Serum amyloid A
(SAA), IL6 and soluble CD14 (sCD14) ELISA measure-
ments were performed according to the manufacturer’s
instructions (Quantikine Human SAA, Quantikine HS
Human IL6, and Quantikine Human sCD14 immunoas-
says; R&D systems, Abingdon, UK). From each separ-
ately run plate a set of controls was chosen and re-run
together to normalize inter-assay variation.
Insulin sensitivity and the augmentation index
In patients with type 1 diabetes, time and dosage of
insulin injections were recorded during the investigation
day. Insulin requirements, measured in units per kilo-
gram body weight, were used as a surrogate marker of
insulin sensitivity [24,25]. In the non-diabetic subjects,
the homeostasis model assessment was used to calculate
insulin resistance (HOMA-IR) index [plasma insulin
(mU/mL) × plasma glucose (mmol/L)/22.5]. Glucose
variability in patients with type 1 diabetes was calculated
as the standard deviation of all six measurements of the
blood glucose between 8:00 and 18:00.
Arterial stiffness was indirectly estimated by the aug-
mentation index (AIx) at fasting and at 12.00 and 16.00.
Briefly, applanation tonometry (SphygmoCor, Atcor
Medical, Sydney, Australia) is a non-invasive method to
estimate arterial stiffness by analyzing arterial pressure
waveforms as described earlier [26,27]. The pulse wave
was recorded from the radial artery of the right arm with
a high-fidelity micromanometer. A model of the central
pressure waveform was synthesized by the SphygmoCor
software using a validated generalized mathematic trans-
formation to calculate the augmentation index and aor-
tic pulse pressure as indicators of arterial stiffness [28].
AIx was corrected for heart rate.
Statistics
Between groups with normally distributed parameters
variation was analysed with Student’s t-test or ANOVA.Non-normally distributed variables were tested with
Mann–Whitney U or Kruskal-Wallis tests. To compare
distributions at two different time points of non-
normally distributed variables Wilcoxon signed rank test
was used. Differences in distributions of several time
points were analysed with Friedman’s test for several
related samples. Pearson’s or Spearman’s correlation ana-
lyses were used as appropriate. Using partial correlation,
the effect of confounding factors was taken into account.
The postprandial response was defined by the area
under the curve (AUC), which was calculated using all
time points between 8:00 and 18:00 with the following
formula [2 hours * ((x1/2) + x2 + x3 + x4 + x5 + (x6/2)),
where x = value at time point]. For the incremental area
(IncA) the area below the first time point * 10 hours was
subtracted from AUC, unless some other time interval is
indicated. All statistical analyses were carried out using
SPSS 15.0 (Chicago, Illinois, USA).
Results
Patients with type 1 diabetes and non-diabetic controls
displayed similar age, gender distribution, BMI, blood
pressure and blood lipid profiles at baseline (Table 1).
Blood pressure lowering medication was used by 38% of
the patients and 9% of the controls (p = 0.005), corre-
sponding values for lipid lowering medication were 24%
and 3% (p = 0.014). Based on 3-day food records, the
mean energy intake did not differ between patients with
type 1 diabetes and controls (2090 ± 420 vs. 2097 ±
702 kcal/24 h; Additional file 1: Table S1). Energy
derived from dietary fats was also similar between the
groups (T1D 41% vs. controls 38%). The energy intake
during the 10-hour study was 2600 kcal, of which 50%
came from fats. Individual meal composition is shown in
Additional file 1: Table S2.
Effects of high-fat meals on serum LPS activity levels
Fasting LPS and LPS-AUC were comparable in patients
with type 1 diabetes and controls [median (25th-75th
quartile): fasting 0.82 (0.57-1.43) vs. 0.90 (0.52-1.24) EU/
ml and AUC 9.8 (6.8-14.1) vs. 8.8 (6.2-11.3)]. Consecu-
tive high-fat meals had only a modest effect on LPS
activity (Figure 1) and an increase in activity was seen in
a similar proportion of controls and patients. After
breakfast (8:00–12:00) the incremental LPS-activity area
(IncA) was higher in the controls compared to the
patients with type 1 diabetes [0.19 (−0.39-1.00) vs. -0.30
(−0.81-0.32); p = 0.032].
Serum lipids showed a positive association with sys-
temic LPS-activity levels. In controls fasting LPS corre-
lated with triglycerides (r = 0.500; p = 0.004) and ApoB-
100 (r = 0.398; p = 0.027). LPS-AUC correlated with
cholesterol-AUC (p = 0.386; p = 0.047), LDL-cholesterol-
AUC (r = 0.361; p = 0.046), and ApoB-100-AUC (r =
Table 1 Clinical characteristics of study participants at fasting
Controls Type 1 diabetes p
Age (yrs) 38.2 ± 10.3 42.5 ± 9.4 ns
Sex (M/F) 18/16 16/21 ns
Duration of diabetes (yrs) - 26 ± 13 -
BMI (kg/m2) 25.2 ± 4.2 26.1 ± 3.6 ns
Systolic blood pressure (mmHg) 129 ± 14 133 ± 17 ns
Diastolic blood pressure (mmHg) 77 ± 10 77 ± 8 ns
HbA1c (%) (mmol/mol) 5.3 ± 0.3 (34 ± 3.3) 8.0 ± 1.3 (64 ± 14.2) <0.001
eGFR (ml/min/1.72 m2) 102 (93–110) 101 (94–114) ns
AER (mg/24 h) 3.4 (2.4–5.2) 7.0 (3.8–13.4) 0.001
Blood glucose (mmol/l) 4.9 ± 0.6 8.7 ± 3.4 <0.001
Cholesterol (mmol/l) 4.7 ± 0.7 4.6 ± 0.7 ns
Triglycerides (mmol/l) 1.0 ± 0.3 0.9 ± 0.5 ns
HDL-chol (mmol/l) 1.3 (1.1–1.7) 1.6 (1.3–1.8) ns
LDL-chol (mmol/l) 2.8 ± 0.7 2.6 ± 0.7 ns
ApoB-100 (mg/dL) 83 (73–93) 72 (66–87) ns
ApoA1 (mg/dL) 138 (123–158) 153 (132–162) ns
ApoB-48 (mg/dL) 3.8 (2.7–5.4) 5.0 (3.7–8.8) 0.014
High-sensitive CRP (mg/l) 1.0 (0.2–2.7) 1.5 (0.3–5.4) ns
Interleukine-6 (pg/ml) 1.2 (0.8–2.0) 1.5 (0.5–3.5) ns
LPS (EU/ml) 0.82 (0.57–1.43) 0.90 (0.52–1.24) ns
Data at fasting are presented as mean ± SD or median (25th-75th quartile). AER – albumin excretion rate, eGFR – estimated glomerular filtration rate.
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fasting LPS and LPS-AUC correlated with CRP (fasting
r = 0.428; p = 0.009, AUC r = 0.338; p = 0.044) and insulin
dose (fasting r = 0.479; p = 0.004, AUC r = 0.528; p = 0.001)
(Additional file 1: Figure S1). To further characterise this
association, we divided patients with type 1 diabetes into
tertiles based on their daily insulin dose. Those in the
highest tertile had significantly higher LPS-AUC (p for
trend 0.003), BMI (p for trend 0.011), systolic and diastolic
blood pressure (p for trend 0.030 and 0.005), triglyceride-
AUC (p for trend 0.004), apoB-100-AUC (p for tendFigure 1 The effects of three high-fat meals on serum LPS-activity
levels. Non-diabetic controls and patients with type 1 diabetes are
indicated with filled circles and open squares, respectively. Lines
indicate median and whiskers 25th – 75th quartile. Meals were given
at 8:00, 12:00, and 16:00 (time on x-axis).0.011), and lower HDL-cholesterol-AUC (p for trend
0.018).
Food records
To investigate whether pre-study dietary intake is asso-
ciated with a higher postprandial endotoxin load, food re-
cords were analysed for the association between LPS-AUC
and energy-, fat-, protein-, and carbohydrate intake adjusted
for BMI. However, no associations between LPS-AUC and
the dietary intake were found. Neither did LPS-AUC cor-
relate with the intake of mono-, poly- and saturated fatty
acids. Fasting LPS, on the other hand, correlated negatively
with the BMI-adjusted fat intake in controls (r = −0.375;
p = 0.038). The same trend was observed in patients with
type 1 diabetes (r = −0.306; p = 0.070).
Inflammatory markers
IL-6 levels increased throughout the day peaking at 16:00
in both the patients with type 1 diabetes (median increase
from fasting: 610% increase) and the controls (570% in-
crease). However, no association between LPS-activity and
IL-6 levels was observed. The inflammatory markers CRP,
sCD14 and SAA varied only modestly during the day and
the patients with type 1 diabetes were no different from
the controls. Fasting leukocyte (5.6 vs. 5.4 E9/l) and neu-
trophil (3.1 vs. 2.8 E9/l) counts were slightly higher in
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leukocyte and neutrophil counts increased significantly
during the 10-hour long examination day. In patients with
type 1 diabetes the increase was blunted: leukocyte delta
change (T1D vs. control 114 vs. 128%; p = 0.022), and neu-
trophil delta change (118 vs. 147%; p = 0.038) between
8:00 and 18:00.
Augmentation index
Patients with type 1 diabetes and controls showed simi-
lar augmentation index (AIx) at fasting but at 12:00 and
16:00 the AIx was higher in patients with type 1 diabetes
(Figure 2). The augmentation index dropped postprandi-
ally in the controls (p for trend 0.029), but the patients
with type 1 diabetes showed no such response (Figure 2).
However, in patients with type 1 diabetes the glucose-
variability during the examination day correlated with
the AIx: 8:00 (r = 0.420, p = 0.017), 12:00 (r = 0.392,
p = 0.048), and 16:00 (r = 0.434, p = 0.013). No asso-
ciation with LPS-activity was observed.
Lipid metabolism
Fasting and postprandial triglyceride concentrations were
similar between the two groups. Serum triglyceride con-
centrations increased after the meals peaking at 14:00 and
18:00 (Additional file 1: Figure S2). Fasting triglyceridesFigure 2 The effects of three consecutive high-fat meals on arterial st
patients with type 1 diabetes compared to controls (grey bars 12:00; p = 0.
during the day (p for trend 0.029). (B) Bracial and aortic systolic blood pres
and heart rate (beats/min) during the research day.predicted postprandial triglyceride response in both
groups (Additional file 1: Figure S2). Those in the highest
fasting triglyceride-tertile had the highest apoB-48-AUC
(T1D p for trend <0.001; controls p = 0.003) and chylo-
micron triglyceride-AUC (p = 0.001; p = 0.004), as well as
the lowest HDL-AUC (p = 0.005; p = 0.002) (Additional
file 1: Figure S2).
Chylomicron markers and LPS uptake
Our next aim was to evaluate if there was a relationship
between chylomicron metabolism and LPS-activity, since
chylomicrons have been described to transport lipid-
soluble endotoxins from the gut [2,5]. ApoB-48, a spe-
cific chylomicron marker, was higher both at fasting
[5.0 (3.7-8.8) vs. 3.8 (2.7-5.4 mg/dL); p = 0.014] and
after the meals [AUC 109 (73–166) vs. 89 (51–128);
p = 0.035] in the patients with type 1 diabetes compared
to the controls (Figure 3). In patients with type 1 dia-
betes apoB-48 correlated positively with the LPS-activity
only after the breakfast (8.00-12.00) (apoB-48-IncA vs.
LPS-IncA r = 0.351; p = 0.036). Although at fasting the
triglyceride-content of the chylomicrons was similar
between the groups, patients with type 1 diabetes
had lower chylomicron triglyceride concentrations
[AUC 1.15 (0.87-1.86) vs. 1.72 (1.10-1.869); p = 0.037]
postprandially.iffness. (A) The augmentation index was higher postprandially in
020 and 16:00; p = 0.028). In controls the arteries significantly relaxed
sure (SBP), diastolic blood pressure (DBP), pulse pressure (PP) mmHg
Figure 3 Impact of three consecutive high-fat meals on serum lipid parameters in non-diabetic controls and patients with type 1 diabetes
(T1D). PLTP - phospholipid transfer protein; CETP - cholesteryl ester transfer protein; PON – Paraoxonase; AUC – area under curve. Data is
presented as median [25th-75th quartile]. Significance of difference at each time point and in AUC between groups are marked as: **p ≤ 0.001;
*p ≤ 0.01; †p ≤ 0.05. Low values are coloured green, high values red.
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in patients with type 1 diabetes at fasting [T1D vs. control
20.2 (12.1-25.3) vs. 24.4 (18.8-32.4 mg/dL); p = 0.022] and
postprandially [AUC 194 (144–253) vs. 260 (202–330);
p = 0.001] (Figure 3). In controls fasting apoE correlated
with ApoB-48 (r = 0.463; p = 0.015) and apoE-AUC with
apoB-48-AUC (r = 0.451; p = 0.018). These correlations
were not seen in patients with type 1 diabetes.
HDL & LPS detoxification
NMR-analysis was used to determine HDL-size distribu-
tions at fasting. Despite similar HDL cholesterol concen-
trations patients with type 1 diabetes had more large HDL
particles (14.3 nm) [441*10−7 ± 176*10−7 vs. 309*10−7 ±
216*10−7 nmol/l; p = 0.007] than controls. In patients with
type 1 diabetes, the number of small-size (8.7 nm) HDL
particles (r = 0.478, p = 0.002) and their total lipid concen-
tration (r = 0.481, p = 0.002) correlated positively with the
LPS-activity.
Serum lipid transfer proteins involved in HDL-model-
ling were elevated in patients with type 1 diabetes com-
pared to controls: PLTP-AUC [67910 (58431–75158) vs.
51315 (47079–59470); p < 0.001] and CETP-AUC [280
(233–313) vs. 250 (204–278); p = 0.007] (Figure 3). On the
other hand, paraoxonase (PON-1)-AUC, an anti-oxidative
enzyme bound to HDL, was lower in patients with type 1
diabetes [191 (135–470) vs. 463 (167–678); p = 0.027]
(Figure 3).
Discussion
We investigated the postprandial effect of three conse-
cutive high-fat meals on endotoxemia, inflammation,
the augmentation index, and lipid metabolism in non-
diabetic controls and patients with type 1 diabetes. The
strengths of our study were that normal eating behaviourwas mimicked by multiple meals during the day, a rela-
tively large number of subjects was included, and a vast
array of metabolic and physiological variables were in-
vestigated in order to characterise the systemic changes.
Importantly, and to the best of our knowledge, postpran-
dial endotoxemia was investigated here for the first time
in patients with type 1 diabetes. We found that the LPS-
activity was only modestly affected by the meals. Patients
with type 1 diabetes showed no significant decrease
in the augmentation index in response to the high-
fat meals and displayed altered chylomicron and HDL
metabolism.
Surprisingly, in non-diabetic controls or patients with
type 1 diabetes, the three consecutive high-fat meals
increased LPS-activity only modestly. Controls displayed
elevated LPS-activity after breakfast and higher post-
prandial triglyceride content in the chylomicrons. The
combination of lower LPS-activity and lower chylo-
micron triglycerides in the patients might be explained
by an increased lipid clearance by a high lipoprotein
lipase-activity [29] or a decreased lipid absorption from
the gut.
A mixed meal containing lipids was previously shown
to be associated with an acute increase in endotoxemia
and inflammation [2,23]. This contrast to our data may
be explained by differences in quantity and quality of fat
between study meals. Furthermore, lipemic interference
on the LAL assay may introduce a bias not accounted
for by previous studies [23]. To overcome this problem
we subtracted the sample background from the absorp-
tion to correct for lipemia, which may explain why the
LPS-activity increased only in a subgroup of the studied
individuals during the day. In addition to LPS, free fatty
acids also act as ligands for TLR4 and can postprandially
trigger inflammation and increase circulating cytokines
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activity and inflammatory markers (IL6, SAA, CD14,
and CRP). Based on previous studies, intravenously
injected LPS seems to have a higher immunostimulatory
potency compared to intestinally derived endotoxins
after a high-fat diet. This discrepancy could possibly be
explained by the efficient dephosphorylation of intestinal
LPS-molecules by intestinal alkaline phosphatase [30].
Increased postprandial endotoxemia is associated with
markers of insulin resistance [31], probably explaining
the strong association between the LPS-AUC and the
body weight adjusted daily insulin dose. In fact, LPS-
AUC was the highest in those with high CRP and a high
insulin dose. A high insulin dose was furthermore asso-
ciated with elevated BMI, systolic blood pressure, and
altered lipid metabolism, supporting an insulin resistant
phenotype.
Patients with type 1 diabetes presented higher AIx, a
surrogate estimate of arterial stiffness, and were unable
to induce relaxation of the arteries in response to the
high-fat diet. The strong correlation with glucose varia-
bility may partly explain this finding. Inflammation and
insulin resistance also cause arterial stiffness although
the process is poorly understood. In patients with type 1
diabetes insulin resistance is associated with the inability
of insulin to decrease central aortic pressure, possibly
predisposing to premature stiffening of large arteries
[32]. Similarly, weight loss in patients with type 2 dia-
betes was shown to decrease arterial stiffness. This was
mainly explained by improved insulin sensitivity and a
reduction in inflammatory factors [33]. We have shown
an acute increase in arterial stiffness and inflammatory
markers in patients with type 1 diabetes during a hy-
perglycaemic clamp [12]. However, in the present study
no such correlation was observed between AIx and
inflammatory markers nor insulin resistance. Also a
direct effect of TRLs on endothelial function is a pos-
sible mechanism [13,14], especially as chylomicron rem-
nants were elevated in patients with type 1 diabetes.
Nevertheless, a number of other mechanisms such as a
deficiency of endothelial vasodilators could have an im-
pact on the endothelial function and the arteries in our
study.
The serum triglycerides increased throughout the day
in response to the high-fat meals. Interestingly, patients
with type 1 diabetes presented conspicuous changes in
chylomicron levels. ApoB-48, a chylomicron structural
protein and as such a marker of intestinal TRL and their
remnants, was elevated in the patients at fasting and
throughout the day compared to controls. Interestingly
uptake of ApoB (−100 and −48) has been described in
leukocytes, leading to activation in response to TRLs
[34]. Furthermore an elevation in apoB-48 is considered
a risk factor for cardiovascular disease [35,36], and highlevels could be caused by a decreased removal of rem-
nants or an increased production of chylomicrons.
Another lipoprotein involved in the catabolism of trigly-
ceride rich particles is apoE [37], which is the master
regulator of chylomicron remnant turnover and facili-
tates their binding to their specific hepatic receptor,
low density lipoprotein-receptor related protein 1, LRP1
[37]. In support of a defect in the clearance capacity of
chylomicron remnants, apoE levels where lower in
patients with type 1 diabetes. Moreover, HDL-bound
apoE has in vitro been shown to induce the activity and
stability of the antioxidative enzyme PON-1 [38]. High
apoB-48, low apoE, and a decrease in PON-1 activity
(anti-oxidative capacity of HDL) together with impaired
AIx response suggest that patients with type 1 diabetes
are likely at higher risk of vascular dysfunction and
cardiovascular disease.
Moreover, HDL has been considered the main detoxi-
fier of circulating endotoxins. The higher proportion of
large HDL particles and higher PLTP activity suggests
a potentially accelerated LPS clearance in patients [39].
Notably in patients, the small-size HDL particle concen-
tration was positively correlated with LPS-activity. These
data suggest differences in the distribution of HDL-
particles and their composition between patients with
type 1 diabetes and controls. Whether intestinal alkaline
phosphatase activity, in addition to potential differences
in HDL protective functions, can explain the lower LPS-
activity in patients with type 1 diabetes is an open
question.
In conclusion, we examined the acute effects of mul-
tiple high-fat meals on endotoxemia, inflammation,
arterial stiffness, and lipid metabolism in patients with
type 1 diabetes and non-diabetic controls. In the pa-
tients the high-fat meals were associated with blunted
decrease in the augmentation index as well as an eleva-
tion of chylomicron remnants (high apoB-48 and low
apoE), which may contribute to a higher risk of cardio-
vascular disease. This effect on the vasculature could
not be explained by an increased inflammatory response
to the high-fat meals because the increase in IL-6 and
circulating leukocytes was similar in the controls and
patients. However, differences in factors related to
HDL/apoB-containing lipoprotein metabolism (PLTP,
CETP and PON-1) suggest that there are changes in
HDL-mediated functions such as inflammation, oxida-
tion and reverse cholesterol transport between the two
groups. Of note, three consecutive high-fat meals during
one day had no significant effect on postprandial LPS-
activity levels in non-diabetic subjects or patients with
type 1 diabetes. Thus, metabolic endotoxemia may be
more central in patients with chronic metabolic dis-
turbances such as obesity, type 2 diabetes, or diabetic
kidney disease.
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Additional file 1: Figure S1. Association of serum LPS-activity levels
with insulin resistance and inflammation in patients with type 1 diabetes.
Mean of LPS-AUC in patients with type 1 diabetes divided by median
of insulin dose (low ≤0.63; high>0.63 units/kg) and hsCRP (low≤1.5;
high>1.5 mg/l). LPS-AUC was increased in patients with a high insulin dose
and high hsCRP (low-low vs. high-high p=0.009; p for trend between all
groups 0.045). Figure S2. Effects of three consecutive high-fat meals on
serum triglyceride, HDL, and chylomicron metabolism. Lipid parameters
divided by fasting triglyceride tertiles during the study day (time on x-axis)
in controls and patients with type 1 diabetes. Mean±SEM. TG-triglycerides;
chylo TG –triglyceride content in chylomicrons. ApoB-48-AUC is higher
(p=0.035) and chylo TG-AUC lower (p=0.037) in patients with type 1
diabetes compared to controls. Table S1. Mean 24h energy and
macronutrient intake based on three-day food records. Table S2. Meal
composition of breakfast, lunch and dinner during the study day.
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